Protein corona–mediated targeting of nanocarriers to B cells allows redirection of allergic immune responses
暂无分享,去创建一个
S. Tenzer | H. Schild | M. Diken | Dominika Hobernik | M. Bros | K. Fischer | S. Grabbe | J. Maxeiner | W. Storck | Limei Shen | Cinja Kappel | A. Verschoor | A. Dzionek | V. Raker | S. Decker | Susanne Krauthäuser | A. Nikolaev | P. Schuster | Petra Schuster | Matthias Bros
[1] S. Durham,et al. Novel approaches and perspectives in allergen immunotherapy , 2017, Allergy.
[2] John D Lambris,et al. Complement component C3 – The “Swiss Army Knife” of innate immunity and host defense , 2016, Immunological reviews.
[3] P. Reche,et al. Novel vaccines targeting dendritic cells by coupling allergoids to nonoxidized mannan enhance allergen uptake and induce functional regulatory T cells through programmed death ligand 1. , 2016, The Journal of allergy and clinical immunology.
[4] M. Jutel,et al. Allergen Immunotherapy: Past, Present, and Future , 2015, Allergy, asthma & immunology research.
[5] A. Boldt,et al. MBL-associated serine proteases (MASPs) and infectious diseases , 2015, Molecular Immunology.
[6] Stefan Tenzer,et al. Protein corona of nanoparticles: distinct proteins regulate the cellular uptake. , 2015, Biomacromolecules.
[7] T. Fahmy,et al. Investigation of peanut oral immunotherapy with CpG/peanut nanoparticles in a murine model of peanut allergy. , 2015, The Journal of allergy and clinical immunology.
[8] H. Schild,et al. IL-10 and Regulatory T Cells Cooperate in Allergen-Specific Immunotherapy To Ameliorate Allergic Asthma , 2015, The Journal of Immunology.
[9] C. Berkland,et al. Multivalent nanomaterials: learning from vaccines and progressing to antigen-specific immunotherapies. , 2015, Journal of pharmaceutical sciences.
[10] Stefan Tenzer,et al. Biomedical applications of ion mobility-enhanced data-independent acquisition-based label-free quantitative proteomics , 2014, Expert review of proteomics.
[11] J. Irache,et al. Nanoparticle based-immunotherapy against allergy. , 2014, Immunotherapy.
[12] Stefan Tenzer,et al. Quantitative profiling of the protein coronas that form around nanoparticles , 2014, Nature Protocols.
[13] K. Gibson-Corley,et al. Development of a Poly (lactic-co-glycolic acid) Particle Vaccine to Protect Against House Dust Mite Induced Allergy , 2014, The AAPS Journal.
[14] M. Carroll,et al. Follicular dendritic cells: dynamic antigen libraries , 2014, Nature Reviews Immunology.
[15] L. Delamarre,et al. Dendritic Cell-Targeted Vaccines , 2014, Front. Immunol..
[16] C. Akdis,et al. Mechanisms of allergen-specific immunotherapy: multiple suppressor factors at work in immune tolerance to allergens. , 2014, The Journal of allergy and clinical immunology.
[17] D. Klinman,et al. Recent progress concerning CpG DNA and its use as a vaccine adjuvant , 2014, Expert review of vaccines.
[18] H. Schild,et al. A Trifunctional Dextran-Based Nanovaccine Targets and Activates Murine Dendritic Cells, and Induces Potent Cellular and Humoral Immune Responses In Vivo , 2013, PloS one.
[19] R. Pike,et al. The molecular switches controlling the interaction between complement proteases of the classical and lectin pathways and their substrates. , 2013, Current opinion in structural biology.
[20] Stefan Tenzer,et al. Rapid formation of plasma protein corona critically affects nanoparticle pathophysiology. , 2013, Nature nanotechnology.
[21] R. O’Donnell,et al. Targeting CD22 in B-cell Malignancies: Current Status and Clinical Outlook , 2013, BioDrugs.
[22] N. Daver,et al. Novel Therapeutic Strategies in Adult Acute Lymphoblastic Leukemia – A Focus on Emerging Monoclonal Antibodies , 2013, Current Hematologic Malignancy Reports.
[23] Andrzej S Pitek,et al. Transferrin-functionalized nanoparticles lose their targeting capabilities when a biomolecule corona adsorbs on the surface. , 2013, Nature nanotechnology.
[24] P. Hari,et al. Characteristics of CliniMACS® System CD34-enriched T cell-depleted grafts in a multicenter trial for acute myeloid leukemia-Blood and Marrow Transplant Clinical Trials Network (BMT CTN) protocol 0303. , 2012, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[25] J. Banchereau,et al. Targeting self- and foreign antigens to dendritic cells via DC-ASGPR generates IL-10–producing suppressive CD4+ T cells , 2012, The Journal of experimental medicine.
[26] John Steel,et al. Programming the magnitude and persistence of antibody responses with innate immunity , 2010, Nature.
[27] B. Goldman,et al. The cancer vaccine roller coaster , 2009, Nature Biotechnology.
[28] I. Bakunina,et al. Structure, biological activity, and enzymatic transformation of fucoidans from the brown seaweeds , 2008, Biotechnology journal.
[29] N. Kaminski,et al. Modulation of Airway Responses to Influenza A/PR/8/34 by Δ9-Tetrahydrocannabinol in C57BL/6 Mice , 2007, Journal of Pharmacology and Experimental Therapeutics.
[30] R. Coffman,et al. Immunotherapy With a Ragweed-Toll-Like Receptor 9 Agonist Vaccine for Allergic Rhinitis , 2007, Pediatrics.
[31] S. Akira,et al. Toll-like receptor 9 controls anti-DNA autoantibody production in murine lupus , 2005, The Journal of experimental medicine.
[32] Q. Hamid,et al. Advances in mechanisms of allergy. , 2004, The Journal of allergy and clinical immunology.
[33] D. Busch,et al. CpG-DNA Aided Cross-Priming by Cross-Presenting B Cells1 , 2004, The Journal of Immunology.
[34] S. Thiel,et al. Lack of mannose-binding lectin-A enhances survival in a mouse model of acute septic peritonitis. , 2002, Microbes and infection.
[35] W. Heath,et al. Defective TCR expression in transgenic mice constructed using cDNA‐based α‐ and β‐chain genes under the control of heterologous regulatory elements , 1998, Immunology and cell biology.
[36] E. Kremmer,et al. Regulation of the B cell response to T-dependent antigens by classical pathway complement. , 1996, Journal of immunology.
[37] R. Karr,et al. Markedly impaired humoral immune response in mice deficient in complement receptors 1 and 2. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[38] P. Butko,et al. Studies of group B streptococcal infection in mice deficient in complement component C3 or C4 demonstrate an essential role for complement in both innate and acquired immunity. , 1995, Proceedings of the National Academy of Sciences of the United States of America.
[39] J. West,et al. B lymphocytes can be competent antigen-presenting cells for priming CD4+ T cells to protein antigens in vivo. , 1995, Journal of immunology.
[40] B. Heyman,et al. Antibodies to murine complement receptor 1 and 2 can inhibit the antibody response in vivo without inhibiting T helper cell induction. , 1995, Journal of immunology.
[41] R. Soltis,et al. Studies on the nature of heat-labile anti-complementary activity in normal human serum. , 1979, Clinical and experimental immunology.
[42] A. M. Prantner,et al. Biological barriers and current strategies for modifying nanoparticle bioavailability. , 2014, Journal of nanoscience and nanotechnology.
[43] Andreas Radbruch,et al. High gradient magnetic cell separation with MACS. , 1990, Cytometry.